Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Appear on S&P Midcap 400 Index Beginning Dec. 30

NEW YORK, Dec. 28 (GenomeWeb News) - Standard & Poor's will add Affymetrix to its S&P MidCap 400 Index Dec. 30, the Index said yesterday.

 

Affy will join Beckman Coulter and Invitrogen, the only other genomic tool vendors tracked by the Index.

 

The Index, launched in 1991, tracks a diverse group of medium-sized UScompanies, according to Streetauthority.com. These companies have a market capitalization of between $2 billion and $10 billion, according to the service.

 

Streetauthority.com said the MidCap 400 "is an important benchmark for many fund managers who invest in this segment" and it "contains solid firms with good track records that are simply not large enough to be included in the much larger S&P 500 index."

 

The Index's current constituents can be seen here.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.